anthracycline

Type: Keyphrase
Name: anthracycline
First reported 20 hours ago - Updated 20 hours ago - 1 reports

Exercise Reduced Cardiovascular Events in Survivors of Childhood Lymphoma

Survivors of childhood Hodgkin lymphoma who went on to regularly complete vigorous exercise had a lower risk of cardiovascular events, independent of their cardiovascular risk profile, than those survivors who did not exercise regularly.In fact, a study ... [Published Cancernetwork.com - 20 hours ago]
Entities: lymphoma, Risk, Toxicity
First reported Oct 29 2014 - Updated Oct 29 2014 - 2 reports

Trastuzumab Plus Vinorelbine May Be an Effective Alternative for HER2-Positive Breast Cancer

the Cancer Therapy Advisor take:According to a new study published in the journal Current Oncology , trastuzumab and vinorelbine is an effective alternative to standard taxane-based chemotherapy for patients with early stage or locally advanced human ... [Published Chemotherapy Advisor - Oct 29 2014]
First reported Oct 29 2014 - Updated Oct 29 2014 - 1 reports

Heart disease can emerge after chemotherapy ends

Cleveland - Stephanie Cirilo was diagnosed with breast cancer in 2000. She had a lumpectomy, eight chemotherapy and 33 radiation treatments.And 10 years later, she was still cancer free, but serious heart problems emerged."The good news is my heart is ... [Published NewsNet 5 - Oct 29 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

Celgene Reports Third Quarter 2014 Operating and -2-

A phase II trial, abound(R) .2L, with ABRAXANE(R) in combination with CC-486 compared to ABRAXANE(R) monotherapy in patients with second-line advanced nonsquamous NSCLC began enrollment in the third quarter. The abound(R) trial program will include additional ... [Published Scottrade - Oct 23 2014]
First reported Oct 18 2014 - Updated Oct 18 2014 - 1 reports

Childhood cancer survivors more susceptible to heart problems

LOS ANGELES (KABC) --Brittany Galan, 22, has been seeing oncologists since she was an infant. At 6-weeks-old, she was diagnosed with leukemia and she was given only a 10 percent survival rate.Miraculously, after six months of chemotherapy, Galan was cured. ... [Published KABC Los Angeles - Oct 18 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Netupitant-Palonosetron Combination Approved by FDA

—FDA on October 10 approved the marketing of netupitant-and-palonosetron capsules for the prevention of nausea and vomiting related to the receipt of cancer chemotherapy.The product, known as Akynzeo, combines the neurokinin-1 receptor antagonist netupitant ... [Published ASHP - Oct 14 2014]
First reported Oct 13 2014 - Updated Oct 14 2014 - 1 reports

Netupitant/Palonosetron (Akynzeo) Gets FDA Nod for Prevention of Chemo-Induced Nausea & Vomiting

First fixed combo targeting two critical pathways in CINVThe FDA has approved netupitant/palonosetron (Akynzeo, Helsinn Group/Eisai Inc.) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer ... [Published PT Community - Oct 13 2014]
First reported Oct 08 2014 - Updated Oct 08 2014 - 1 reports

Eisai announces launch of Halaven in Australia

Eisai Australia Pty. Ltd., a pharmaceutical sales subsidiary of Eisai Co., Ltd., has launched Halaven eribulin mesylate in Australia. Halaven is an anticancer agent discovered and developed by Eisai. It is currently approved in more than 55 countries ... [Published Individual.com - Oct 08 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Anthracycline-Dependent Cardiotoxicity and Extracellular Matrix Remodeling

The mechanisms of anthracycline-dependent cardiotoxicity have been studied widely, with the suggested principal mechanism of anthracycline damage being the generation of reactive oxygen species by iron-anthracycline complexes, leading to lipid peroxidation ... [Published CHEST - Oct 07 2014]
First reported Oct 02 2014 - Updated Oct 02 2014 - 1 reports

EISAI : Launches anticancer agent halaven in australia; first exclusively marketed product to mark commencement of full-scale operations

Release date- 01102014 - Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , ' Eisai ') announced today that its Australian pharmaceutical sales subsidiary Eisai Australia Pty. Ltd. (Eisai Australia) has launched Halaven (eribulin mesylate) in the ... [Published 4 Traders - Oct 02 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Halaven (Eribulin) Provides Clinical Benefit Without an Adverse Effect on Quality of Life: Data Presented at ESMO

/PRNewswire/ --FOR EMEA MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTSAdditional Pooled Phase III Data Presented at ESMO Show Significantly Improved Overall Survival for Eribulin Compared to Standard Therapies in Locally Advanced or Metastatic Breast Can ... [Published FinanzNachrichten.de - Sep 26 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

Clinigen Confident For Current Year, Raises Dividend As Profit Rises

LONDON ( Alliance News ) - Clinigen Group PLC Wednesday expressed confidence for the current year and raised its total dividend, as it saw profit rise in the year to the end of June.The speciality pharmaceuticals company proposed a total dividend of 3.1 ... [Published HispanicBusiness.com - Sep 24 2014]

Quotes

And even with the heart damage that resulted from chemo, she's taking medication for it and said, "I feel wonderful. I exercise, do everything normally. I have no problems, so life is very good."
"If I didn't take the medication that I take now, I don't know where I'd be" she said
Release date- 01102014 - Eisai Co Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , " Eisai ') announced today that its Australian pharmaceutical sales subsidiary Eisai Australia Pty. Ltd. (Eisai Australia) has launched Halaven (eribulin mesylate) in the country."
Associate Professor Paul Mainwaring, medical oncologist at The Mater Hospital, Brisbane, said: "New treatment options for Australian women with locally advanced or metastatic breast cancer are welcomed by doctors, patients and their families as there remains a high unmet need for improved therapies. People who have been progressed on previous therapies urgently need new treatments that have demonstrated an overall survival benefit, so the availability of Halaven is very good news."

More Content

All (28) | News (28) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Exercise Reduced Cardiovascular Events in Survi... [Published Cancernetwork.com - 20 hours ago]
Trastuzumab Plus Vinorelbine May Be an Effectiv... [Published Chemotherapy Advisor - Oct 29 2014]
Neoadjuvant Therapy of Early Stage Human EGFR 2... [Published General Medicine eJournal - Oct 29 2014]
Heart disease can emerge after chemotherapy ends [Published NewsNet 5 - Oct 29 2014]
Celgene Reports Third Quarter 2014 Operating an... [Published Scottrade - Oct 23 2014]
Childhood cancer survivors more susceptible to ... [Published KABC Los Angeles - Oct 18 2014]
Netupitant-Palonosetron Combination Approved by... [Published ASHP - Oct 14 2014]
Netupitant/Palonosetron (Akynzeo) Gets FDA Nod ... [Published PT Community - Oct 13 2014]
Eisai announces launch of Halaven in Australia [Published Individual.com - Oct 08 2014]
Anthracycline-Dependent Cardiotoxicity and Extr... [Published CHEST - Oct 07 2014]
Chemotherapy risky for medical staff [Published The Japan News - Oct 06 2014]
EISAI : Launches anticancer agent halaven in au... [Published 4 Traders - Oct 02 2014]
Doxorubicin Attenuates Serotonin-Induced Long-T... [Published Journal of Neuroscience - Oct 01 2014]
ESMO 2014: Eisai’s Halaven could provide better... [Published Pharma Letter - Oct 01 2014]
Liposome composition for targeting egfr receptor [Published PharmCast - Sep 28 2014]
Trastuzumab Trial Shows Fewer Cardiac Problems ... [Published Oncology Times - Sep 27 2014]
Halaven (Eribulin) Provides Clinical Benefit Wi... [Published FinanzNachrichten.de - Sep 26 2014]
Guidance to Help Cancer Survivors Avoid Cardiac... [Published Theheart.org - Sep 26 2014]
Clinigen Confident For Current Year, Raises Div... [Published HispanicBusiness.com - Sep 24 2014]
Mabion Signed An Agreement For The Realization ... [Published BioSpace - Sep 23 2014]
CTI BioPharma, Servier team up to develop and c... [Published PharmaBiz - Sep 19 2014]
MicroRNA-140-5p as a tumor suppressor and sensi... [Published PharmCast - Jul 18 2014]
Expanded EU approval sets Halaven on course [Published BioPortfolio - Jul 03 2014]
Variants of humanized immunomodulatory monoclon... [Published PharmCast - Apr 15 2014]
Targeting of bone marrow neovasculature [Published PharmCast - Apr 11 2014]
Tumor-initiating cells and methods of use [Published PharmCast - Apr 09 2014]
Delivery system for cytotoxic drugs by bispecif... [Published PharmCast - Mar 02 2014]
Pharmaceutical Research Interindividual Variabi... [Published BioPortfolio - Feb 23 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.